COL17A1 and neoplasm: The most well-established theories include activation of antibody-secreting B cells, inhibition of immunosuppressive regulatory T-lymphocytes, cross-reaction between anti-BP180 antibodies since BP180 is expressed by many tumor cells, or the triggering of clinically undetectable emerging BP by ICI [3,8,34,35,36,37].